1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Wesana Health Holdings Inc.

Wesana Health Holdings Inc.

WSNAF
Wesana Health Holdings Inc.US flagOther OTC
0.02
USD
- -
- -
341,000.00Market Cap
Wesana Health Holdings Inc.
WSNAF
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2020
2021
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.01
-0.01
-0.01
-1.48
-0.25
-0.05
-0.03
Basic EPS, GAAP
-0.01
- -
-0.01
-0.52
-0.22
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.17
-0.01
-0.21
0.11
-0.15
-0.13
-0.14
Book Value per Share
0.02
-0.01
0.01
0.26
0.03
-0.01
-0.02
Tangible Book Value per Share
13
13
13
23
34
35
35
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-288.67
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-34
-9
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-288.67
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
6
1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
8
1
- -
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
1
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
743.07%
-128.25%
Free Cash Flow
- -
2,091.26%
-88.74%
Net Income, GAAP
- -
4,600.97%
-79.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.15
-0.08
0.01
- -
-0.25
2023
-0.02
-0.02
0.01
- -
-0.05
2024
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Lescarden Inc. (LCAR)
Revelation Biosciences, Inc. (REVBU)
European Medical Solutions (0RGO.L)
SeaStar Medical Holding Corporation (ICUCW)
Terns Pharmaceuticals, Inc. (TERN)
Abpro Holdings, Inc. (ABPO)
Business
Wesana Health Holdings Inc. (CSE: WESA; OTCQB: WSNAF) maintains no significant operations, having previously focused on the development and delivery of psychedelic and naturally-sourced therapies, including psilocybin-based formulations and protocols such as SANA-013, to treat traumatic brain injury (TBI), major depressive disorder, post-traumatic stress disorder, anxiety, and related neurological, psychological, and mental health ailments caused by trauma; the company offered evidence-based clinical research, academic partnerships, and care delivery services through Wesana Clinics and Wesana Solutions. Founded in 2007 and headquartered in Chicago, Illinois, with an address at 433 West Van Buren Street, Suite 200, Wesana Health operates in the life sciences and psychedelics sector, targeting patients and healthcare providers primarily in the United States and Canada. Recent developments include a strategic review of its care delivery division announced alongside a private placement tranche closure, evaluating options such as asset sales to streamline focus and advance SANA-013's Phase 1b/2a study for major depressive disorder following positive FDA feedback; earlier efforts encompassed the 2021 acquisition of PsyTech Health for expanded psychiatric capabilities and mental health clinics in Illinois, alongside a $4 million convertible note financing led by The Conscious Fund and Ambria Capital to fund preclinical and clinical work on TBI therapies and regulatory filings with the FDA and Health Canada.

Company News

APIChatGPT

  • newsfilecorp.com

    Wesana Health Announces Change to The Board of Directors

  • newsfilecorp.com

    Wesana Health Announces Restructuring of Promissory Note Receivable

  • newsfilecorp.com

    CSE Bulletin: Symbol Change - Inactive Designation - Wesana Health Holdings Inc. (WESA)

  • benzinga.com

    Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana

  • proactiveinvestors.com

    Wesana Health CEO leveraging personal and professional experience to help patients achieve better mental health outcomes